Value
5.4/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 9.0 |
NUVB · Why this verdict
Why Nuvation Bio (NUVB) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Nuvation Bio is a pre-profitability biotech with a 26% short interest and put/call ratio of 9.0, but analysts project more than 140% upside and the company maintains a strong current ratio, leaving the risk-reward asymmetric and highly speculative.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Analysts project 140% upside to their target price, yet 26% of the float is sold short, creating a large gap between institutional price expectations and bearish market positioning. Sentiment breakdown | The stock price rises above $8 within 12 months as analyst targets get reaffirmed or raised, compressing the short interest. | →Stable |
| CounterHigh short interest of 26% and an elevated put/call ratio of 9.0 suggest that well-informed traders see near-term catalysts as insufficient to justify the current price, and the company has missed earnings expectations in 2 of the last 4 quarters. | ||
A current ratio of 5.6 indicates the company holds substantial near-term liquidity relative to its liabilities, reducing the immediate risk of a dilutive capital raise. Quality breakdown | The current ratio remains above 3.0 over the next 12 months, indicating the company is not forced into emergency financing. | →Stable |
| CounterFree cash flow is negative at 70% of revenue, meaning the cash cushion is being consumed; at this burn rate the strong current ratio could deteriorate within 1 to 2 years without new financing. | ||
On-balance volume is rising and the 200-day moving average slope is still positive at +6.7% per month, suggesting that buyers are accumulating shares despite the death cross pattern. Momentum breakdown | Price rises above the 200-day moving average within 6 months as accumulation continues, confirming the recovery setup. | →Stable |
| CounterThe setup remains a death cross pattern, and historically a death cross combined with high short interest leads to further underperformance before any recovery materializes. | ||
Nuvation Bio missed earnings estimates by 23.6% and 91.1% in the two most recent quarters, with an average surprise of negative 26.8%, signaling that actual financial performance is deteriorating faster than analyst models assume. Earnings | The company posts an earnings surprise above negative 10% in at least 2 of the next 4 quarters, stabilizing the miss trend. | →Stable |
| CounterCash-burning pre-revenue biotechs often miss estimates as clinical timelines slip; the deep misses may reflect timing differences rather than fundamental deterioration. | ||
Analysts project 140% upside to their target price, yet 26% of the float is sold short, creating a large gap between institutional price expectations and bearish market positioning.
→StableSentiment breakdown
- Expectation
- The stock price rises above $8 within 12 months as analyst targets get reaffirmed or raised, compressing the short interest.
CounterHigh short interest of 26% and an elevated put/call ratio of 9.0 suggest that well-informed traders see near-term catalysts as insufficient to justify the current price, and the company has missed earnings expectations in 2 of the last 4 quarters.
A current ratio of 5.6 indicates the company holds substantial near-term liquidity relative to its liabilities, reducing the immediate risk of a dilutive capital raise.
→StableQuality breakdown
- Expectation
- The current ratio remains above 3.0 over the next 12 months, indicating the company is not forced into emergency financing.
CounterFree cash flow is negative at 70% of revenue, meaning the cash cushion is being consumed; at this burn rate the strong current ratio could deteriorate within 1 to 2 years without new financing.
On-balance volume is rising and the 200-day moving average slope is still positive at +6.7% per month, suggesting that buyers are accumulating shares despite the death cross pattern.
→StableMomentum breakdown
- Expectation
- Price rises above the 200-day moving average within 6 months as accumulation continues, confirming the recovery setup.
CounterThe setup remains a death cross pattern, and historically a death cross combined with high short interest leads to further underperformance before any recovery materializes.
Nuvation Bio missed earnings estimates by 23.6% and 91.1% in the two most recent quarters, with an average surprise of negative 26.8%, signaling that actual financial performance is deteriorating faster than analyst models assume.
→StableEarnings
- Expectation
- The company posts an earnings surprise above negative 10% in at least 2 of the next 4 quarters, stabilizing the miss trend.
CounterCash-burning pre-revenue biotechs often miss estimates as clinical timelines slip; the deep misses may reflect timing differences rather than fundamental deterioration.
Per-dimension breakdown
Quality
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 1.9 |
| Current ratio | 5.6 |
| FCF quality | 0.0 |
| Moat | 6.5 |
| Rule of 40 | 9.5 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -70% of revenue
- ▸Rule of 40: 2529 (elite)
Growth
5.0/10data confidence 50%Momentum
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 9.2 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 3.6 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 3.7 |
| Analyst rating | 8.0 |
| Price target | 10.0 |
- ▸Light analyst coverage (9.0) — signal dampened
- ▸Analyst upside: 106%
Insider
4.4/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 3.5 |
| holder change | 5.1 |
- ▸Modest insider selling — $1,220,589 (0.054% of mkt cap)
Peer rank
3.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.7 |
| quality rank | 1.8 |
| growth rank | 10.0 |
- ▸Industry growth leader
Technical
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.1 |
| support resistance | 2.9 |
| 52w position | 2.3 |
| gap | 7.5 |
- ▸Extreme gap down (-13.0%) - potential reversal
Risk (lower is worse)
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.9 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 4.8 |
| debt equity | 6.9 |
- ▸High short interest justified: 26%
- ▸High IV: 100%
- ▸Above max pain $2
Catalyst
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 8.0 |
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (8)
- MOMENTUM:7.4>=5.5
- ASYMMETRY:5.3>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:42d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
5.30
Upside
+79.4%
Downside
15.0%
Sizing output
AVOID
SetupMOMENTUM_CONT — Trend continuation, RSI 62, MACD bullish
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — Beta 1.56>1.3, MCap $2.2B<$5B
Investment implication
The F-path SELL output reflects an overall score of 5.2 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Momentum at 7.4) was not enough to lift the adjusted overall above the threshold. Current asymmetry R:R is 5.30 — supplementary context, not the trigger for this path.
The strongest dimensions are Momentum at 7.4, Sentiment at 7.2, and Catalyst at 6.3; the weakest are Risk (lower is worse) at 3.2, Technical at 3.5, and Peer rank at 3.9. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 5.30 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Analysts project 140% upside to their target price, yet 26% of the float is sold short, creating a large gap between institutional price expectations and bearish market positioning.
Trip ifShort interest rises above 30% of float or the stock price falls below $3 for more than 5 trading days.
- P2A current ratio of 5.6 indicates the company holds substantial near-term liquidity relative to its liabilities, reducing the immediate risk of a dilutive capital raise.
Trip ifCurrent ratio falls below 2.5 in any reported quarter.
- P3On-balance volume is rising and the 200-day moving average slope is still positive at +6.7% per month, suggesting that buyers are accumulating shares despite the death cross pattern.
Trip ifPrice falls below the 200-day moving average and on-balance volume declines for more than 60 consecutive days.
- P4Nuvation Bio missed earnings estimates by 23.6% and 91.1% in the two most recent quarters, with an average surprise of negative 26.8%, signaling that actual financial performance is deteriorating faster than analyst models assume.
Trip ifEPS surprise falls below negative 50% in at least 2 of the next 4 quarters.